Safety and Efficacy of High-Dose Interleukin-2 Therapy in Patients With Brain Metastases

Journal of Immunotherapy

Volumn 25, Issue 1, 2002, Pages 82-87

  Guirguis, Lisa M ^a   Yang, James C ^a   White, Donald E ^a   Steinberg, Seth M ^a   Liewehr, David J ^a   Rosenberg, Steven A ^a   Schwartzentruber, Douglas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Brain metastases; Interleukin 2; Melanoma; Safety

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CONSCIOUSNESS DISORDER; DISORIENTATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VOMITING;

ADULT; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0036140228     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200201000-00009     Document Type: Article

References (14)

1. Lotze MT, Dallal RM, Kirkwood JM, Flickinger JC. Cutaneous melanoma. In: DeVita Jr, VT Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 2012-69.
2. Balch CM, Soong S, Shaw HM, Urist MM, McCarthy WH. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S, eds. Cutaneous Melanoma. Philadelphia, PA: J.B. Lippincott, 1992: 165-87.
3. Jennings SB, Linehan WM. Renal, perirenal, and ureteral neoplasms. In: Gillenwater JY, Grayhack JT, Howards SS, Duckett JW, eds. Adult and Pediatric Urology. St. Louis, MO: Mosby; 1996: 643-94.
4. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228: 307-19.
5. Schwartzentruber DJ. Interleukin-2: Clinical applications. Principles of administration and management of side effects. In: Rosenberg SA, ed. Principles and Practice of the Biologic Therapy of Cancer. Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 32-50.
6. Citterio G, Di Lucca G, Scaglietti U, Gilberti S, Baldini M, Rugarli C. Reduction of brain metastasis after immunotherapy with interleukin-2 for stage IV renal cell cancer. Acta Oncol 1997; 36: 228-228.
7. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7.
8. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994; 271: 907-13.
9. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85: 622-32.
10. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 1994; 86: 1159-66.
11. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, decarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17: 968-75.
12. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998; 83: 797-805.
13. Guleria AS, Yang JC, Topalian SL, et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. J Clin Oncol 1994; 12: 2714-22.
14. Hurst R, White DE, Heiss J, Lee DS, Rosenberg SA, Schwartzentruber DJ. Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated? J Immunother 1999; 22: 356-62.